Head to Head Review: Flag Ship Acquisition (ETHZ) & Its Peers

Flag Ship Acquisition (NASDAQ:ETHZ) is one of 450 public companies in the “Pharmaceutical Preparations” industry, but how does it contrast to its competitors? We will compare Flag Ship Acquisition to related businesses based on the strength of its earnings, valuation, analyst recommendations, institutional ownership, profitability, dividends and risk.

Insider & Institutional Ownership

4.1% of Flag Ship Acquisition shares are owned by institutional investors. Comparatively, 39.5% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 5.4% of Flag Ship Acquisition shares are owned by insiders. Comparatively, 13.8% of shares of all “Pharmaceutical Preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations for Flag Ship Acquisition and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flag Ship Acquisition	1	0	0	0	1.00
Flag Ship Acquisition Competitors	4780	9954	15974	366	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 72.63%. Given Flag Ship Acquisition’s competitors stronger consensus rating and higher probable upside, analysts clearly believe Flag Ship Acquisition has less favorable growth aspects than its competitors.

Valuation and Earnings

This table compares Flag Ship Acquisition and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Flag Ship Acquisition	N/A	-$6.17 million	-0.13
Flag Ship Acquisition Competitors	$439.18 million	-$68.87 million	-9.40

Flag Ship Acquisition’s competitors have higher revenue, but lower earnings than Flag Ship Acquisition. Flag Ship Acquisition is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Flag Ship Acquisition and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Flag Ship Acquisition	N/A	-141.25%	-80.77%
Flag Ship Acquisition Competitors	-2,625.49%	-359.63%	-43.39%

Risk & Volatility

Flag Ship Acquisition has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Flag Ship Acquisition’s competitors have a beta of 10.34, indicating that their average share price is 934% more volatile than the S&P 500.

Summary

Flag Ship Acquisition competitors beat Flag Ship Acquisition on 9 of the 13 factors compared.

Flag Ship Acquisition Company Profile

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.